Expand GLUE Menu
GLUE MENU

GLUE Latest Press Releases

-- June 2, 2026 --

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- May 20, 2026 --

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences Globe Newswire 7:00 AM

-- May 7, 2026 --

Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates Globe Newswire 7:00 AM

-- May 5, 2026 --

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- April 20, 2026 --

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors Globe Newswire 7:00 AM

-- March 17, 2026 --

Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates Globe Newswire 7:00 AM

-- March 16, 2026 --

Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer Globe Newswire 7:00 AM

-- February 24, 2026 --

Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU) Globe Newswire 7:00 AM

-- February 23, 2026 --

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences Globe Newswire 7:00 AM
Market Data Delayed 15 Minutes